The Burden of Neurosarcoidosis

Autor: Marjolein Drent, Barney J. Stern, Lesley Ann Saketkoo, Mareye Voortman
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Pulmonary and Respiratory Medicine
cognition
medicine.medical_specialty
peripheral neuropathy
small fiber neuropathy
Disease
paralysis
Critical Care and Intensive Care Medicine
FATIGUE
BRONCHOALVEOLAR LAVAGE
03 medical and health sciences
0302 clinical medicine
EVERYDAY COGNITIVE FAILURE
LONG-TERM OUTCOMES
Central Nervous System Diseases
QUALITY-OF-LIFE
medicine
Paralysis
Humans
SMALL-FIBER NEUROPATHY
sarcoidosis
Intensive care medicine
Physical Therapy Modalities
CNS SARCOIDOSIS
neurosarcoidosis
business.industry
CENTRAL-NERVOUS-SYSTEM
Aseptic meningitis
Neurosarcoidosis
medicine.disease
Magnetic Resonance Imaging
Review article
Early Diagnosis
Peripheral neuropathy
030228 respiratory system
CORNEAL CONFOCAL MICROSCOPY
Quality of Life
Biomarker (medicine)
SKIN BIOPSY
Sarcoidosis
medicine.symptom
business
Biomarkers
Immunosuppressive Agents
030217 neurology & neurosurgery
Zdroj: Seminars in Respiratory and Critical Care Medicine. 41(05):641-651
ISSN: 1069-3424
DOI: 10.1055/s-0040-1710576
Popis: Neurosarcoidosis (NS) is an often severe, destructive manifestation with a likely under-reported prevalence of 5 to 15% of sarcoidosis cases, and in its active phase demands timely treatment intervention. Clinical signs and symptoms of NS are variable and wide-ranging, depending on anatomical involvement. Cranial nerve dysfunction, cerebrospinal parenchymal disease, aseptic meningitis, and leptomeningeal disease are the most commonly recognized manifestations. However, non-organ-specific potentially neurologically driven symptoms, such as fatigue, cognitive dysfunction, and small fiber neuropathy, appear frequently.Heterogeneous clinical presentations and absence of any single conclusive test or biomarker render NS, and sarcoidosis itself, a challenging definitive diagnosis. Clinical suspicion of NS warrants a thorough systemic and neurologic evaluation hopefully resulting in supportive extraneural physical exam and/or tissue findings. Treatment targets the severity of the manifestation, with careful discernment of whether NS reflects active potentially reversible inflammatory granulomatous disease versus inactive postinflammatory damage whereby functional impairment is unlikely to be pharmacologically responsive. Non-organ-specific symptoms are poorly understood, challenging in deciphering reversibility and often identified too late to respond to conventional immunosuppressive/pharmacological treatment. Physical therapy, coping strategies, and stress reduction may benefit patients with all disease activity levels of NS.This publication provides an approach to screening, diagnosis, disease activity discernment, and pharmacological as well as nonpharmacological treatment interventions to reduce disability and protect health-related quality of life in NS.
Databáze: OpenAIRE